Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

REGN

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:REGN
DateTimeSourceHeadlineSymbolCompany
14/10/202123:12Dow Jones NewsRegeneron Cocktail Gets FDA Priority Review for Covid-19 Treatment, PreventionNASDAQ:REGNRegeneron Pharmaceuticals Inc
14/10/202122:21PR Newswire (US)FDA Accepts REGEN-COV® (casirivimab and imdevimab) for Priority Review for Treatment and Prophylaxis of COVID-19NASDAQ:REGNRegeneron Pharmaceuticals Inc
12/10/202107:15PR Newswire (US)Regeneron to Report Third Quarter 2021 Financial and Operating Results and Host Conference Call and Webcast on November 4, 2021NASDAQ:REGNRegeneron Pharmaceuticals Inc
02/10/202105:18Dow Jones NewsRegeneron Pharmaceuticals Down Over 5%, on Pace for Largest Percent Decrease Since March 2020 -- Data TalkNASDAQ:REGNRegeneron Pharmaceuticals Inc
30/09/202121:07Dow Jones NewsRegeneron Covid-19 Trial Meets Primary EndpointNASDAQ:REGNRegeneron Pharmaceuticals Inc
30/09/202115:00PR Newswire (US)New REGEN-COV™ (casirivimab and imdevimab) Data Show Supportive Results in Patients Hospitalized with COVID-19NASDAQ:REGNRegeneron Pharmaceuticals Inc
30/09/202107:00PR Newswire (US)New England Journal of Medicine Publishes Positive Phase 3 Trial Results for REGEN-COV™ (casirivimab and imdevimab) to Treat COVID-19NASDAQ:REGNRegeneron Pharmaceuticals Inc
29/09/202122:11TipRanksFDA Accepts Regeneron’s sBLA for Metastatic Cervical Cancer TreatmentNASDAQ:REGNRegeneron Pharmaceuticals Inc
28/09/202121:50Dow Jones NewsRegeneron Gets FDA Priority Review of Libtayo in Advanced Cervical CancerNASDAQ:REGNRegeneron Pharmaceuticals Inc
28/09/202121:00PR Newswire (US)FDA Accepts Libtayo® (cemiplimab-rwlc) for Priority Review for Advanced Cervical CancerNASDAQ:REGNRegeneron Pharmaceuticals Inc
21/09/202114:59PR Newswire (US)New Dupixent® (dupilumab) Data in Patients as Young as Six Years Old With Moderate-to-Severe Atopic Dermatitis to Be Presented at WCPD and EADVNASDAQ:REGNRegeneron Pharmaceuticals Inc
20/09/202101:30PR Newswire (US)ESMO Late-breaking Data Show Libtayo® (cemiplimab) and Chemotherapy First-line Treatment Combination Significantly Improved Overall Survival in Patients with Advanced NSCLCNASDAQ:REGNRegeneron Pharmaceuticals Inc
18/09/202106:02Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:REGNRegeneron Pharmaceuticals Inc
17/09/202106:02Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:REGNRegeneron Pharmaceuticals Inc
16/09/202106:05Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:REGNRegeneron Pharmaceuticals Inc
15/09/202121:00TipRanksRegeneron Signs Third COVID-19 Drug Supply Agreement with U.S. GovernmentNASDAQ:REGNRegeneron Pharmaceuticals Inc
15/09/202107:33PR Newswire (US)Regeneron Announces New U.S. Government Agreement to Purchase Additional Doses of REGEN-COV™ (casirivimab and imdevimab) Antibody CocktailNASDAQ:REGNRegeneron Pharmaceuticals Inc
14/09/202106:02Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:REGNRegeneron Pharmaceuticals Inc
09/09/202106:05PR Newswire (US)Regeneron Announces Investor Conference PresentationsNASDAQ:REGNRegeneron Pharmaceuticals Inc
04/09/202106:05Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:REGNRegeneron Pharmaceuticals Inc
04/09/202106:04Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:REGNRegeneron Pharmaceuticals Inc
02/09/202106:06Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:REGNRegeneron Pharmaceuticals Inc
01/09/202106:03Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:REGNRegeneron Pharmaceuticals Inc
31/08/202106:26Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:REGNRegeneron Pharmaceuticals Inc
30/08/202121:58Dow Jones NewsPfizer Study of Abrocitinib Vs Dupixent Meets Main EndpointsNASDAQ:REGNRegeneron Pharmaceuticals Inc
30/08/202121:07Dow Jones NewsRegeneron, Sanofi: Dupixent Hits Endpoints in Atopic Dermatitis Under Age 6NASDAQ:REGNRegeneron Pharmaceuticals Inc
30/08/202114:59PR Newswire (US)Dupixent® (dupilumab) Pivotal Trial Meets All Primary and Secondary Endpoints Becoming First Biologic Medicine to Significantly Reduce Signs and Symptoms of Moderate-to-severe Atopic Dermatitis in Children as Young as 6 MonthsNASDAQ:REGNRegeneron Pharmaceuticals Inc
28/08/202106:12Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:REGNRegeneron Pharmaceuticals Inc
25/08/202106:06Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:REGNRegeneron Pharmaceuticals Inc
24/08/202121:00PR Newswire (US)Regeneron Announces Encouraging Topline Phase 2 Data of High-dose aflibercept in Wet Age-related Macular DegenerationNASDAQ:REGNRegeneron Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:REGN